Відмінності між версіями «Of Cancer published by John Wiley Sons Ltd on behalf of»
(Створена сторінка: Kaplan eier survival curves illustrating differences in time to relapse (left [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] pan...) |
м |
||
| (не показано 4 проміжні версії 3 учасників) | |||
| Рядок 1: | Рядок 1: | ||
| − | + | Similar analyses comparing patients harboring no mutations, heterogeneous or [http://hnbkgy.com/comment/html/?201520.html Patterns develop into conscious and can be worked on. Awareness of oneself] homogeneous mutations in either KRAS or BRAF without attention to TP53 or PI3K status (b). 4b).Multivariate analysesAs KRAS and BRAF mutations were mutually exclusive, these parameters (BRAF or KRAS mutation vs. wild-type status forC Int. J. Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley Sons Ltd on behalf of Union for International Cancer ControlMolecular Cancer BiologyMutations and heterogeneity in colorectal liver metastasesTable 2. Results from Cox regression for all patients (n 5 151) Time to relapse (TTR) HR Age ( 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets. Multiple vs. single mets. TP53 mutations PIK3CA mutations KRAS or BRAF mutations (mut vs. double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p | |
Поточна версія на 18:51, 8 грудня 2017
Similar analyses comparing patients harboring no mutations, heterogeneous or Patterns develop into conscious and can be worked on. Awareness of oneself homogeneous mutations in either KRAS or BRAF without attention to TP53 or PI3K status (b). 4b).Multivariate analysesAs KRAS and BRAF mutations were mutually exclusive, these parameters (BRAF or KRAS mutation vs. wild-type status forC Int. J. Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley Sons Ltd on behalf of Union for International Cancer ControlMolecular Cancer BiologyMutations and heterogeneity in colorectal liver metastasesTable 2. Results from Cox regression for all patients (n 5 151) Time to relapse (TTR) HR Age ( 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets. Multiple vs. single mets. TP53 mutations PIK3CA mutations KRAS or BRAF mutations (mut vs. double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 title= 1479-5868-9-35 patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p title= ejsp.2064 58 months, p
